Clinical trial
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
NCT00908921 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
- Lead sponsor
- Sanofi
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- September 30, 2010
- Enrollment
- 391 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.